Open AccessPhase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Author(s) -
Michael Lim,
Michael Weller,
Ahmed Idbaïh,
Joachim P. Steinbach,
Gaetano Finocchiaro,
Raju R. Raval,
George Ansstas,
Joachim M. Baehring,
Jennie Taylor,
Jérôme Honnorat,
Kevin Petrecca,
Filip De Vos,
Antje Wick,
Ashley Sumrall,
Solmaz Sahebjam,
Ingo K. Mellinghoff,
Masashi Kinoshita,
Mustimbo Roberts,
Ruta Slepetis,
Deepti Warad,
David Leung,
Michelle Lee,
David A. Reardon,
Antonio Omuro
Publication year - 2022
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/noac116
Subject(s) - temozolomide , medicine , nivolumab , placebo , regimen , chemoradiotherapy , dacarbazine , radiation therapy , clinical endpoint , gastroenterology , randomized controlled trial , oncology , chemotherapy , cancer , immunotherapy , pathology , alternative medicine
Nearly all patients with newly diagnosed glioblastoma experience recurrence following standard-of-care radiotherapy (RT) + temozolomide (TMZ). The purpose of the phase III randomized CheckMate 548 study was to evaluate RT + TMZ combined with the immune checkpoint inhibitor nivolumab (NIVO) or placebo (PBO) in patients with newly diagnosed glioblastoma with methylated MGMT promoter (NCT02667587).